
Conflict of interest statement: The authors of this manuscript have no potential 
conflicts of interest to declare.


2246. Ann Pathol. 2017 Feb;37(1):79-89. doi: 10.1016/j.annpat.2016.12.013. Epub 2017
Jan 19.

[Current events in immunotherapy for upper aerodigestive tract cancer].

[Article in French]

Outh-Gauer S(1), Le Tourneau C(2), Broudin C(1), Scotte F(3), Roussel H(4), Hans 
S(5), Mandavit M(6), Tartour E(7), Badoual C(8).

Author information: 
(1)Service d'anatomie pathologique, hôpital européen Georges-Pompidou, AP-HP, 20,
rue Leblanc, 75015 Paris, France.
(2)Département d'oncologie médicale, institut Curie, 75005 Paris, France; Unité
Inserm U900, 75005 Paris, France.
(3)Unité fonctionnelle de soins oncologiques de support, pôle cancérologie
spécialités, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015
Paris, France.
(4)Service d'anatomie pathologique, hôpital européen Georges-Pompidou, AP-HP, 20,
rue Leblanc, 75015 Paris, France; Inserm U 970, équipe 10, PARCC, faculté Paris
Descartes, 75015 Paris, France.
(5)Service ORL et chirurgie cervico-faciale, hôpital européen Georges-Pompidou,
AP-HP, 20, rue Leblanc, 75015 Paris, France.
(6)Inserm U 970, équipe 10, PARCC, faculté Paris Descartes, 75015 Paris, France.
(7)Inserm U 970, équipe 10, PARCC, faculté Paris Descartes, 75015 Paris, France; 
Service d'immunologie biologique, hôpital européen Georges-Pompidou, AP-HP, 20,
rue Leblanc, 75015 Paris, France.
(8)Service d'anatomie pathologique, hôpital européen Georges-Pompidou, AP-HP, 20,
rue Leblanc, 75015 Paris, France; Inserm U 970, équipe 10, PARCC, faculté Paris
Descartes, 75015 Paris, France. Electronic address: cecile.badoual@aphp.fr.

Head and neck (HN) carcinomas (mostly represented by squamous cell carcinomas
[SCC]) still have a poor prognosis, which could be dramatically improved with
immunotherapy. Tumor's microenvironment changes, caused by many endogenous or
exogenous events, can correlate with prognosis and therapeutic response. Here, we
review recent data regarding HNSCC, nasopharyngeal carcinomas (NPC) and salivary 
gland malignant tumors, all three being potential target of immunotherapies.
About half of HNSCC exhibit PD-L1 expression, this expression being upregulated
in HPV-positive tumors. In recent clinical trials, a better therapeutic response 
to anti-PD-1 has been obtained in patients with higher PD-L1 expression. Food and
Drug Administration (FDA) approved the use of these therapeutics without the
screening of patients regarding PD-L1 status. Activation status, density and
localisation of TIL as well as PD-L2, γ-interferon, inflammatory cytokines,
epithelial-mesenchymal transition phenotype and mutational burden may all be
potential therapeutic response markers. In Epstein-Barr Virus (EBV)-induced
nasopharyngeal non-keratinizing cancer, PD-L1 is over-expressed compared to EBV
negative-tumors. A 22 % response rate has been observed under
anti-PD-1 treatment, among PD-L1-positive HNSCC patients. There is little data
regarding microenvironment of salivary gland cancer. PD-L1 shows great
heterogeneity in localisation, when expressed. A 11 % response rate has been
obtained under anti-PD-1 treatment among PD-L1-positive NPC patients. A better
understanding of immune checkpoint regulation processes needs to be achieved to
allow patients with HN carcinomas to benefit from these promising
immunotherapies.

Copyright © 2016 Elsevier Masson SAS. All rights reserved.

DOI: 10.1016/j.annpat.2016.12.013 
PMID: 28111039  [Indexed for MEDLINE]
